We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

ETHICON ENDO-SURGERY

Ethicon Endo-Surgery, Inc. a subsidiary of the Johnson & Johnson group of companies, develops, manufactures, and mark... read more Featured Products: More products

Download Mobile App




Biological Sealant Stems Moderate Bleeding During Surgery

By HospiMedica International staff writers
Posted on 01 Jul 2019
Print article
Image: The Vistaseal laparoscopic dual applicator (Photo courtesy of Ethicon).
Image: The Vistaseal laparoscopic dual applicator (Photo courtesy of Ethicon).
An innovative airless spray delivers the clotting proteins fibrinogen and thrombin to stop bleeding when standard bleeding control techniques, such as sutures, are impractical.

The Ethicon Endo-Surgery (Ethicon; Cincinnati, OH, USA) Vistaseal Open and Laparoscopic dual applicators (available in 35 cm and 45 cm lengths) combine biologics with device technology to address mild to moderate surgical bleeding. The airless spray products are the result of a broad partnership between Ethicon and plasma-derived medicine manufacturer Grifols (Barcelona, Spain), which developed the human fibrin sealant for use when standard bleeding control techniques are inadequate.

The thrombin-catalyzed conversion of fibrinogen to fibrin consists of three reversible steps, with thrombin being involved in only the first step, which is a limited proteolysis to release fibrinopeptides (FpA and FpB) from fibrinogen to produce the fibrin monomer. In the second step, the fibrin monomers combine to form intermediate polymers through noncovalent interactions. In the third and final step, the intermediate polymers aggregate to form the fibrin clot, which stems the bleed.

“Ethicon’s biosurgery portfolio offers a broad array of technologies that address intraoperative bleeding, which is among the most difficult challenges facing surgeons and their patients,” said Oray Boston, president of worldwide biosurgery at Ethicon. “Our partnership with Grifols will leverage our strengths in device technology, with Grifols’ strengths in plasma-derived medicines to expand our portfolio and accelerate innovation in the fast growing field of biosurgery.”

“Grifols is committed to applying its plasma leadership to its collaboration with Ethicon, whose strengths in device technology and market success in reaching millions of patients worldwide enable us to make important advances in biosurgery and the control of surgical bleeding,” said Eduardo Herrero, president of Grifols Bioscience.

Johnson & Johnson (JNJ; New Brunswick, NJ, USA), the parent company of Ethicon, estimates that between one- and two-thirds of open surgery procedures experience disruptive bleeding events, with potentially harmful complications from both fluid and air leaks. In addition, they say that these numbers are expected to rise as more patients present with comorbidities and other factors (such as aspirin and blood thinners) increase the risk of surgical bleeding, due to an aging population.


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Medical Gas Blender
BlenderBuddy 1

Print article

Channels

Critical Care

view channel
Image: The permeable wearable electronics developed for long-term biosignal monitoring (Photo courtesy of CityUHK)

Super Permeable Wearable Electronics Enable Long-Term Biosignal Monitoring

Wearable electronics have become integral to enhancing health and fitness by offering continuous tracking of physiological signals over extended periods. This monitoring is crucial for understanding an... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The PATHFAST hs-cTnI-II high-sensitivity troponin assay has been developed for the PATHFAST Biomarker Analyzer (Photo courtesy of Polymedco)

POC Myocardial Infarction Test Delivers Results in 17 Minutes

Chest pain is the second leading cause of emergency department (ED) visits by adults in the United States, generating over 7 million visits annually. In the event of a suspected heart attack, physicians... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.